
Three train manufacturers have been fined a total of 56.4 billion won ($43 million) for collusion.
The companies — Hyundai Rotem, Woojin Industrial Systems and Dawonsys — are the only train manufacturers in the country.
According to the Fair Trade Commission (KFTC), the companies coordinated on bidding for 11 accounts valued at 2 trillion won. The GTX was included on the list of projects for which the companies had agreements.
The collusion started when Hyundai Rotem proposed in 2013 to Woojin Industrial Systems that they agree to limit competition.
Hyundai Rotem was created in 1999 when three companies, Hyundai Precision Industry, Daewoo Heavy Industries & Machinery and Hanjin Heavy Industries & Construction, merged.
The first collaboration was a 2013 bid for the Gimpo Goldline, a railway that connects Gimpo city with the Gimpo International Airport in Gangseo District, Seoul.
They started colluding for other bids, including for projects related to Seoul lines No. 2, No. 5 and No. 9 and Korail’s Airport Railroad Express (AREX), which connects Seoul with Incheon International Airport, and the Busan subway.
In the agreement, Hyundai Rotem would be the only bidder, and Woojin Industrial System would exclusively supply the parts.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas